Figure 1 illustrates CXCR4 signaling, its regulation by plerixafor and Dasatinib, and its role in cell survival. Furthermore, plerixafor interferes with the tumor stroma interactions that are known to be responsible for resistance to therapy (Eulberg et al., 2022). It is known that CXCR4 allows cancer stem cell (CSC) survival and immune evasion within the TME (Dzobo et al., 2020). The gene discussed is CXCR4; the disease is neoplasm.